The mpox vaccine is approved in in Canada, the European Union, Mexico, Singapore, Switzerland, the UK and the US. Credit: Creative Design nacional/Shutterstock.

Bavarian Nordic has received a $63m contract from the US government to produce further bulk product and final freeze-dried doses of the JYNNEOS smallpox/mpox vaccine.

The order, received from the US Biomedical Advanced Research and Development Authority, aims to replenish the bulk product inventory and support the manufacture of one million vaccine doses.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The bulk product, which constitutes the majority of the contract’s value, is essential to restocking the inventory depleted during the 2022 mpox outbreak response.

Replenishment is vital to meet the terms of Bavarian Nordic’s existing contract, which includes the supply of a freeze-dried version of the vaccine for US smallpox preparedness.

The deal will facilitate the production of one million freeze-dried vaccines utilising portions of the bulk inventory.

Although the bulk of the vaccine is scheduled for manufacture in 2025, with international orders in mind to address the ongoing mpox outbreak, the delivery of the freeze-dried doses is set for 2026.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Bavarian Nordic president and CEO Paul Chaplin stated: “This award further strengthens the orders for the public preparedness business for 2025 and beyond and is yet another resounding endorsement of MVA-BN as the leading smallpox/mpox vaccine.

“While the current mpox outbreak is a reminder of how vulnerable the international community remains to infectious diseases, we are dedicated to assist all governments and organisations, not only in the current public health emergency but beyond to ensure the equitable access to our smallpox/mpox vaccine.”

Marketed as JYNNEO, the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) non-replicating mpox vaccine is approved in Canada, the European Union, Mexico, Singapore, Switzerland, the UK and the US.

Initially developed as a smallpox vaccine in partnership with the US government, MVA-BN was designed to ensure the vaccine supply suitable for the entire population, including those who are immunocompromised and advised against traditional replicating smallpox vaccines.

The latest development comes after the European Medicines Agency (EMA) approved the use of Bavarian Nordic’s mpox vaccine in adolescents, increasing the chances for its use in this age group in Africa.

The Global Alliance for Vaccines and Immunization recently entered an advance purchase agreement with Bavarian Nordic to secure 500,000 doses of the mpox vaccine.